Cethromycin - Wikipedia
网页Cethromycin, trade name Restanza (initially known as ABT-773 [1] [2]) is a ketolide antibiotic undergoing research for the treatment of community acquired pneumonia (CAP) [1] [3] [4] [5] and for the prevention of post-exposure inhalational anthrax, and was given an "orphan drug" status for this indication. [6]
Cethromycin: Uses, Interactions, Mechanism of Action - DrugBank …
网页2008年3月19日 · Cethromycin is a ketolide antibiotic with broad-spectrum activity against Gram-positive, Gram-negative, and atypical bacteria that may be useful for treating several conditions including community-acquired pneumonia, inhalation anthrax, …
Cethromycin: A Promising New Ketolide Antibiotic for Respiratory ...
网页2012年4月5日 · Cethromycin is a new ketolide antibiotic being investigated for use in respiratory tract infections. To review its pharmacology, in vitro susceptibilities, pharmacokinetics, efficacy, safety, and drug interactions, we conducted a MEDLINE search restricted to English-language articles citing cethromycin or ABT-773 (its original …
Cethromycin - an overview | ScienceDirect Topics
网页CAP remains the primary infectious cause of death in the United States. Cethromycin (Restanza, Advanced Life Sciences) is a novel, once-a-day, oral ketolide under development for the treatment of CAP and for prevention of post-exposure inhalational anthrax and was given an ‘orphan drug’ status for this indication.
Cethromycin: a new ketolide antibiotic - PubMed
网页Cethromycin displays in vitro activity against selected gram-positive, gram-negative, and atypical bacteria. The proposed indication of cethromycin is treatment of mild to moderate community-acquired bacterial pneumonia in patients aged 18 years or older.
Cethromycin: A New Ketolide Antibiotic - Hanine Mansour, Elias B ...
网页2016年12月21日 · Cethromycin displays in vitro activity against selected gram-positive, gram-negative, and atypical bacteria. The proposed indication of cethromycin is treatment of mild to moderate community-acquired bacterial pneumonia in …
Cethromycin - an overview | ScienceDirect Topics
网页Cethromycin is a once-daily ketolide that originated from research by Abbott Laboratories. It is effective against Streptococcus pneumoniae, including multidrug-resistant isolates, Haemophilus influenzae, Moraxella catarrhalis, Chlamydophila pneumoniae, Mycoplasma pneumoniae, and Legionella pneumophila.
The antimicrobial activity of cethromycin against
网页Cethromycin is a new ketolide antibiotic being developed for use in respiratory tract infections, demonstrates more potent antibacterial effects than its predecessor telithromycin, and displays potent inhibition of both gram-positive and gram-negative respiratory pathogens .
Cethromycin | C42H59N3O10 | CID 156417 - PubChem
网页Cethromycin is a 3-keto (ketolide) derivative of erythromycin A with an 11,12-carbamate group and an O-6-linked aromatic ring system. Cethromycin represents a joint development effort by Abbott Laboratories, Taisho Pharmaceuticals, and Advanced Life Sciences, intended to be marketed under the trade name Restanza for the treatment of community ...
Cethromycin - an overview | ScienceDirect Topics
网页Cethromycin is a new fluoroketolide with a reported high potency against Gram-positive, Gram-negative bacteria and atypicals including mycoplasma and ureaplasma. It has also in vitro activity against penicillin- and macrolide-resistant Gram-positive organisms, possibly due to a higher affinity for the target site on the ribosomal unit [32].